Iron Dextran Dosing for Iron Deficiency Anemia

Dosing Protocols

The American Journal of Kidney Diseases recommends administering 500-1000 mg of low molecular weight iron dextran as a single infusion diluted in 250 mL of normal saline over 1 hour, with a mandatory 25 mg test dose, for adult patients with iron deficiency anemia 1, 2
The National Comprehensive Cancer Network suggests that this approach is more economical and convenient than multiple smaller doses 1
A 25 mg test dose must be given as a slow IV push with 1-hour observation before administering the full therapeutic dose, as recommended by the Journal of the National Comprehensive Cancer Network and the American Journal of Hematology 3, 4
The total dose infusion can be repeated as needed to maintain adequate iron stores, according to the American Journal of Kidney Diseases 2

The Journal of the National Comprehensive Cancer Network and the American Journal of Hematology recommend always administering a 25 mg test dose via slow IV push and waiting 1 hour before proceeding with the therapeutic dose 3, 4
Low molecular weight iron dextran carries a boxed FDA warning for anaphylaxis risk, as reported by the American Journal of Hematology 5, 4
Active infection or bacteremia is an absolute contraindication for IV iron therapy, according to the Journal of the National Comprehensive Cancer Network 3
A history of anaphylaxis to iron dextran is also an absolute contraindication, as stated by the American Journal of Hematology 4

The National Comprehensive Cancer Network provides a modified Ganzoni formula to calculate the total iron deficit: Dose = 0.0442 × (desired Hgb - observed Hgb) × lean body weight + (0.26 × lean body weight) 3
If the calculated dose exceeds 1000 mg, the remaining dose should be given after 4 weeks if there is an inadequate response, as recommended by the Journal of the National Comprehensive Cancer Network 3

The American Journal of Kidney Diseases recommends waiting 2 weeks after doses ≥1000 mg before checking iron parameters for an accurate assessment 2
Transferrin saturation should be >20%, serum ferritin >100 ng/mL, and hemoglobin 11-12 g/dL, according to the American Journal of Kidney Diseases 2
Iron therapy should be withheld if transferrin saturation >50% or ferritin >800 ng/mL, as stated by the American Journal of Kidney Diseases 2

Arthralgias and myalgias are common dose-related effects that occur with larger doses, as reported by the American Journal of Kidney Diseases 1
These effects are not anaphylactic reactions and resolve spontaneously, according to the American Journal of Kidney Diseases 1

The American Journal of Hematology recommends never using high molecular weight iron dextran, only low molecular weight (INFeD) is acceptable 5, 4
The Journal of the National Comprehensive Cancer Network and the American Journal of Hematology emphasize that the test dose should not be skipped, as it is mandatory despite low anaphylaxis rates 3, 4
The American Journal of Kidney Diseases advises against checking iron parameters too early after large doses (wait 2 weeks minimum) 2
The Journal of the National Comprehensive Cancer Network states that IV iron therapy should not be administered during active infection, as it is an absolute contraindication 3
The American Journal of Kidney Diseases recommends informing patients about arthralgias/myalgias with doses >500 mg so they understand this is expected and not an allergic reaction 1, 2

The American Journal of Hematology notes that newer formulations like iron sucrose and ferric gluconate do not require test doses but necessitate multiple visits to achieve adequate repletion 5, 3, 4
Iron dextran remains the most cost-effective option when total dose infusion is feasible, according to the American Journal of Hematology and the American Journal of Kidney Diseases 5, 1